Articles Posted in Mass Torts

Glucose monitor lawsuits are being filed by people who say continuous glucose monitoring systems failed when they needed them most. These lawsuits involve Dexcom G6, Dexcom G7, Abbott FreeStyle Libre 3, and Abbott FreeStyle Libre 3 Plus sensors, apps, and receivers that allegedly provided inaccurate glucose readings, missed high- or low-glucose alerts, failed early, or failed to warn users that glucose data had stopped reporting.

This is no small complaint for someone with diabetes who relies on these monitors. A continuous glucose monitor can drive decisions about insulin, food, sleep, exercise, and emergency care. When a sensor falsely reports low glucose, a patient may eat carbohydrates or delay insulin. When a device misses a low alert, a patient may seize, lose consciousness, fall, or die. When a high glucose event is missed, the result can be prolonged hyperglycemia, diabetic ketoacidosis, hospitalization, or worse.  Of course, a malfunctioning glucose monitor typically causes more minor injuries and inconveniences.

Our lawyers are looking for serious glucose monitor cases involving serious injury or death.

Our lawyers are handling AFFF firefighting foam lawsuits around the country.

This page provides the most recent news and updates on the AFFF firefighting foam class action lawsuit and our prediction of the settlement amounts that plaintiffs with AFFF cancer lawsuits can expect to receive. You will not get more updated news on the AFFF litigation anywhere else.

Our AFFF firefighting foam lawyers believe the defendants will settle most of these lawsuits this year (2026) before a single trial.  Why? They will follow the same pattern as the water contamination lawsuits they settled for billions of dollars.  In those cases, we saw the defendants’ apparent preference for settlement over the uncertainties of a trial.  This makes sense; the AFFF lawsuits are strong cases.

For sickle cell patients and families, Oxbryta was supposed to be a lifeline. Instead, it left many worse off–facing new health crises, hospitalizations, and in some cases, unthinkable loss. Now, Oxbryta lawsuits are uncovering what Pfizer knew and when it knew it.

Oxbryta is a prescription drug developed by Global Blood Therapeutics and later acquired by Pfizer. It was voluntarily recalled in September 2024 after new evidence revealed that it caused serious and potentially fatal complications, including vaso-occlusive crises and organ damage.

This page looks at Oxbryta lawsuits and their potential settlement value.

Oxbryta is a prescription drug made by Pfizer that was recalled in September 2024 after evidence revealed that it caused a number of very serious and potentially fatal health problems, including vaso-occlusive crisis and organ damage. Continue reading

Artificial intelligence has changed how people create, edit, and distribute images. But it has also opened a dangerous new frontier for exploitation and abuse. One of the most alarming developments is the rise of AI-generated sexual deepfakes: fake images or videos that can make it appear as though a real person was nude, sexualized, or involved in conduct that never happened.

The Grok deepfake lawsuit is one of the clearest early tests of whether AI companies can be held legally responsible when their tools generate or enable nonconsensual sexual images. These claims are not just about bad users. They are about product design, warnings, safeguards, profit, notice, and whether a company can release a powerful image-generation tool into the world and then blame victims when the predictable abuse occurs.

If your image, your child’s image, or someone you love was used in an AI-generated sexual deepfake, treat it like evidence in a serious civil case. Because it is. Screenshots help, but URLs, account names, timestamps, takedown requests, medical records, school records, employment records, and platform responses can all help. You do not need every piece of evidence to call, but the more we can preserve, the stronger the case may be.

Our lawyers are helping victims who want to bring a Gardasil HVP vaccine lawsuit throughout the United States.  Our law firm is particularly focused on ovarian failure cases that lead to infertility in women who have taken Gardasil in the last few years.

Gardasil is a vaccine intended to prevent human papillomavirus (HPV), which can sometimes lead to cervical cancer in women. Gardasil was developed by the embattled pharmaceutical company Merck & Co.

Merck obtained FDA approval for Gardasil in 2006 based on deceptive research and clinical trials that misrepresented the vaccine’s efficacy while concealing its safety risks and side effects. Merck then launched an aggressive and highly misleading marketing campaign to include millions of parents vaccinating their pre-teen daughters with Gardasil.

Consumer product safety testing has confirmed that several aerosol dry shampoo products contained dangerously high levels of benzene, a known human carcinogen. That discovery led to product recalls, consumer class action lawsuits, and continuing questions about whether long-term use of benzene-contaminated dry shampoo can increase the risk of leukemia, lymphoma, multiple myeloma, aplastic anemia, and other blood-related cancers.

This page explains the dry shampoo lawsuits, the benzene testing, the product recalls, the current Unilever and IGK settlement status, the list of products involved in recalls or litigation, and the potential value of dry shampoo cancer claims.

We provide this page solely to educate consumers and potential victims about the litigation, the science, and the issues that drive these cases.

Our attorneys also provide the latest updates on the Zantac class action lawsuit (including the disastrous news that the class action judge dismissed all federal court Zantac lawsuits). This page was updated on April 21, 2026.

Zantac Cancer Lawsuit Updates 2026

The Zantac litigation has been a rollercoaster, filled with major victories, setbacks, and unexpected twists. From the initial discovery of NDMA contamination to the collapse of certain cases and the resurgence of others, this litigation has taken many turns.

If you swallowed a wire bristle from a grill brush or found a metal fragment in your food after cleaning your grill, you are not imagining things or overreacting. A wire bristle from a grill cleaning brush can break off during normal use, stick to a burger or hot dog without anyone seeing it, and end up in your throat, stomach, or intestines. These injuries can range from sharp throat pain and trouble swallowing to bowel perforation requiring emergency surgery.

The danger is not new. The CDC warned about grill brush bristle injuries years ago, after reports of people suffering internal injuries from tiny metal bristles that detached from brushes and were swallowed with grilled food. What changed in 2026 is that federal regulators took major action. The U.S. Consumer Product Safety Commission announced large recalls involving Weber and Nexgrill metal wire bristle grill brushes because detached bristles can stick to grills or food and cause serious internal injuries that may require medical treatment or surgery.

Together, the Weber and Nexgrill recalls cover more than 13 million grill brushes. Weber recalled about 3.2 million brushes after reports of bristles detaching, including cases where consumers required medical treatment. Nexgrill recalled more than 10.2 million brushes after at least 68 reports or reviews involving detached bristles, including five reports of consumers swallowing metal bristles and needing medical treatment to remove them from the throat or digestive tract. If you or someone in your family was hurt after using one of these brushes, there may be a product liability claim against the manufacturer.

Ocaliva was supposed to protect your liver. Instead, for many, it destroyed it.

 Ocaliva was sold as a treatment for primary biliary cholangitis, a chronic disease that damages the bile ducts in the liver. It came to market with promise. It left the market under a cloud of serious liver injury, transplant, and death.

By late 2025, the FDA had withdrawn approval of Ocaliva after concluding the postmarketing evidence showed excess liver transplants and deaths, and did not verify the clinical benefit the company needed to prove. Intercept then pulled the drug from the United States market.

Contact Information